Get the Stockscreener App
2.07
2.48%
0.05
After Hours:
2.16
0.09
+4.35%
Gain Therapeutics Inc stock is traded at $2.07, with a volume of 901.31K.
It is up +2.48% in the last 24 hours and up +18.29% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$2.02
Open:
$2.1
24h Volume:
901.31K
Relative Volume:
1.71
Market Cap:
$74.41M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.8818
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
+13.74%
1M Performance:
+18.29%
6M Performance:
+31.01%
1Y Performance:
+4.55%
1-Day Range:
$2.00
$2.20
1-Week Range:
$1.80
$2.40
52-Week Range:
$1.41
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.07 | 72.62M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Is it time to cut losses on Gain Therapeutics Inc.July 2025 Pullbacks & AI Optimized Trading Strategy Guides - newser.com
Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World
What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Will Gain Therapeutics Inc. stock benefit from sector rotation2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com
Is Gain Therapeutics Inc. stock cheap at current valuation2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
Analyzing drawdowns of Gain Therapeutics Inc. with statistical tools2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Can technical indicators confirm Gain Therapeutics Inc.’s reversal2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
What drives Gain Therapeutics Inc stock priceRisk Management Strategies & Investment Timing Techniques - earlytimes.in
What analysts say about Gain Therapeutics Inc stockEarnings Surprise Analysis & Superior Portfolio Growth - earlytimes.in
How to escape a deep drawdown in Gain Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st
Custom strategy builders for tracking Gain Therapeutics Inc.Gap Up & Free Reliable Trade Execution Plans - newser.com
What MACD signals say about Gain Therapeutics Inc.July 2025 Gainers & Community Supported Trade Ideas - newser.com
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):